Menstrual and Other Female Reproductive System Disorders DRG Reimbursement

DRG 761 addresses menstrual and other female reproductive system disorders without Complication or Comorbidity or Major Complication or Comorbidity, covering uncomplicated gynecologic medical and surgical admissions. It matters for inpatient reimbursement because it identifies lower-severity cases with correspondingly lower Medicare payments and helps determine payment classification for hospitals.

DRG 761 Overview

DRG 761 covers hospital admissions for menstrual and other female reproductive system disorders without Complication or Comorbidity or Major Complication or Comorbidity. Typical cases include noncomplicated procedures and medical management for conditions such as abnormal uterine bleeding, benign adnexal masses, and certain gynecologic pain syndromes. This Diagnosis-Related Group groups patients with lower expected resource use, which affects average inpatient payment under Medicare payment policies. Understanding the clinical scope aids coding, billing, and reimbursement classification.

DRG 761 Overview

Acute procedural and perioperative management studies: Trials assessing short-term procedural interventions (for example, endometrial ablation, hysteroscopy-guided polypectomy, or minimally invasive surgical management of symptomatic fibroids) compare different techniques, anesthesia protocols, or perioperative medical regimens in premenopausal and perimenopausal patients admitted for heavy menstrual bleeding or other non-malignant reproductive tract disorders. These studies enroll patients presenting with significant symptoms requiring inpatient or same-day surgical treatment and measure metrics such as hemostasis success, intraoperative blood loss, transfusion need, length of stay, and early complication rates. Findings directly inform hospital resource utilization, operative pathway standardization, and reimbursement considerations for DRG 761 by clarifying which approaches reduce complications and short-stay admissions.
Comparative effectiveness and symptom-control pharmacotherapy trials: Randomized or pragmatic trials comparing pharmacologic strategies (for instance hormonal regimens, antifibrinolytics, or novel non-hormonal agents) for controlling heavy menstrual bleeding, dysmenorrhea, or other benign reproductive disorders in outpatient-eligible but recently hospitalized patients. These studies focus on reproductive-aged patients with recurrent symptoms that led to recent inpatient evaluation, assessing reductions in bleeding days, need for future procedures, quality-of-life scores, and avoidance of rehospitalization over several months. Results are relevant to payers and providers because effective medical management that reduces readmissions and procedure rates can lower overall costs associated with DRG 761 and guide coverage and step-therapy policies.
Health services, care-transition, and long-term outcomes research: Observational cohort studies or implementation trials evaluating discharge planning, outpatient follow-up pathways, patient education, and long-term outcomes (including return visits, subsequent procedures, fertility outcomes, and patient-reported symptom resolution) for patients hospitalized for benign menstrual and other female reproductive system disorders. These studies typically enroll diverse inpatient populations across hospitals to identify predictors of unplanned readmission, disparities in access to conservative versus surgical care, and the impact of coordinated outpatient care on downstream utilization over 6–12 months. This research informs hospital quality metrics, DRG-based cost containment strategies, and payer decisions about investment in transitional care programs that can reduce avoidable readmissions and optimize allocation of resources for this patient group.

Acute procedural and perioperative management studies: Trials assessing short-term procedural interventions (for example, endometrial ablation, hysteroscopy-guided polypectomy, or minimally invasive surgical management of symptomatic fibroids) compare different techniques, anesthesia protocols, or perioperative medical regimens in premenopausal and perimenopausal patients admitted for heavy menstrual bleeding or other non-malignant reproductive tract disorders. These studies enroll patients presenting with significant symptoms requiring inpatient or same-day surgical treatment and measure metrics such as hemostasis success, intraoperative blood loss, transfusion need, length of stay, and early complication rates. Findings directly inform hospital resource utilization, operative pathway standardization, and reimbursement considerations for DRG 761 by clarifying which approaches reduce complications and short-stay admissions.
Comparative effectiveness and symptom-control pharmacotherapy trials: Randomized or pragmatic trials comparing pharmacologic strategies (for instance hormonal regimens, antifibrinolytics, or novel non-hormonal agents) for controlling heavy menstrual bleeding, dysmenorrhea, or other benign reproductive disorders in outpatient-eligible but recently hospitalized patients. These studies focus on reproductive-aged patients with recurrent symptoms that led to recent inpatient evaluation, assessing reductions in bleeding days, need for future procedures, quality-of-life scores, and avoidance of rehospitalization over several months. Results are relevant to payers and providers because effective medical management that reduces readmissions and procedure rates can lower overall costs associated with DRG 761 and guide coverage and step-therapy policies.
Health services, care-transition, and long-term outcomes research: Observational cohort studies or implementation trials evaluating discharge planning, outpatient follow-up pathways, patient education, and long-term outcomes (including return visits, subsequent procedures, fertility outcomes, and patient-reported symptom resolution) for patients hospitalized for benign menstrual and other female reproductive system disorders. These studies typically enroll diverse inpatient populations across hospitals to identify predictors of unplanned readmission, disparities in access to conservative versus surgical care, and the impact of coordinated outpatient care on downstream utilization over 6–12 months. This research informs hospital quality metrics, DRG-based cost containment strategies, and payer decisions about investment in transitional care programs that can reduce avoidable readmissions and optimize allocation of resources for this patient group.

OpenPayer

Menstrual and Other Female Reproductive System Disorders without CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 761 policy alerts

DRG 761 Overview

OpenPayer

Menstrual and Other Female Reproductive System Disorders without CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 761 policy alerts

DRG 761 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References